Horus Pharma, the second largest independent ophthalmological laboratory in France and a leading European player, announced a strategic collaboration with Klinge Biopharma GmbH and Formycon AG for the semi-exclusive commercialization of Formycon’s Eylea biosimilar, FYB203 (aflibercept), under the brand name Baiama, in selected European countries.
The agreement marks Horus Pharma’s entry into the biosimilar segment, expanding its therapeutic portfolio and reinforcing its position as a comprehensive ophthalmology specialist. The commercialization will include France—the company’s home market—as well as other selected European territories.
FYB203/Baiama, a biosimilar to Eylea® (aflibercept), will be Horus Pharma’s first biosimilar product. The launch supports the company’s strategic goal of strengthening its presence in the retina segment, complementing its existing range of treatments, including therapies for diabetic macular edema.
“The addition of FYB203/Baiama to our portfolio is a transformative milestone for Horus Pharma,” said Claude Claret, CEO of Horus Pharma. “With Baiama, we reinforce our presence in the retina field and complete our ophthalmology portfolio. Our ambition is to provide patients and practitioners with innovative, safe, and cost-effective therapeutic solutions across the entire spectrum of eye health.”
Retinal diseases such as neovascular age-related macular degeneration (nAMD) remain among the leading causes of severe vision loss in Europe, particularly among older adults. With aging populations, the demand for effective and affordable treatments continues to grow.
FYB203 (aflibercept), a vascular endothelial growth factor (VEGF) inhibitor, offers ophthalmologists a cost-efficient alternative to the reference biologic Eylea, targeting abnormal blood vessel formation in the retina. The biosimilar received marketing authorization from the European Commission in January 2025 under the brand name Baiama.
Horus Pharma’s entry into the biosimilar space reflects its commitment to innovation, patient access, and healthcare sustainability. Biosimilars are expected to play a growing role in improving access to high-quality therapies while reducing costs for healthcare systems.
“By bringing FYB203 to our markets, Horus Pharma reinforces its role as a trusted partner for healthcare professionals and a driver of innovation access in ophthalmology,” added Claret. “We are convinced that biosimilars represent the future of therapeutic access and will play an increasingly central role in sustainable healthcare.”
Founded in 2003, Horus Pharma is recognized for its expertise in preservative-free ophthalmic formulations and has built a strong presence across France and Europe. Formycon AG, based in Germany, is an independent developer of biosimilars targeting key therapeutic areas such as ophthalmology, immunology, and immuno-oncology.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!